US 11,857,612 B2
Bacillus Calmette-Guerin (BCG) and antigen presenting cells for treatment of bladder cancer
Patrick Soon-Shiong, Culver City, CO (US)
Assigned to NantCell, Inc., Culver City, CA (US)
Filed by NantCell, Inc., Culver City, CA (US)
Filed on Dec. 15, 2022, as Appl. No. 18/066,648.
Application 17/747,253 is a division of application No. 16/932,331, filed on Jul. 17, 2020, granted, now 11,364,291, issued on Jun. 21, 2022.
Application 18/066,648 is a continuation of application No. 17/747,253, filed on May 18, 2022, granted, now 11,554,167.
Claims priority of provisional application 62/875,663, filed on Jul. 18, 2019.
Prior Publication US 2023/0210974 A1, Jul. 6, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/04 (2006.01); A61K 35/15 (2015.01); A61K 39/39 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/04 (2013.01) [A61K 35/15 (2013.01); A61K 39/00114 (2018.08); A61K 39/001119 (2018.08); A61K 39/39 (2013.01); A61K 2039/515 (2013.01); A61K 2039/585 (2013.01)] 17 Claims
 
1. A vaccine composition comprising:
1) immunotherapeutic primed antigen presenting cells, wherein the antigen presenting cells are isolated from a urine sample or bladder mucosa of an immunotherapeutic treated subject; and
2) an IL-15:IL-15Rα fusion protein complex, wherein the antigen presenting cells are exposed ex-vivo to the IL-15:IL-15Rα fusion protein complex.